Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 10, Issue 4, Pages -
Publisher
Springer Nature
Online
2019-04-11
DOI
10.1038/s41419-019-1555-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression
- (2017) Yi-Hui Wu et al. INTERNATIONAL JOURNAL OF CANCER
- miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin
- (2015) X Zhu et al. ONCOGENE
- Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
- (2015) Antonella Cusimano et al. Oncotarget
- Solanum Incanum Extract Downregulates Aldehyde Dehydrogenase 1-Mediated Stemness and Inhibits Tumor Formation in Ovarian Cancer Cells
- (2015) Yi-Hui Wu et al. Journal of Cancer
- The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells
- (2014) Ying-Hsi Lin et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake
- (2014) Ramachandran Rashmi et al. PLoS One
- Epidemiology of Malignant Cervical, Corpus Uteri and Ovarian Tumours - Current Data and Epidemiological Trends
- (2013) A. Waldmann et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- PKB/Akt-Dependent Regulation of Cell Motility
- (2013) G. Xue et al. JNCI-Journal of the National Cancer Institute
- COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer
- (2013) Y-H Wu et al. ONCOGENE
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- TWIST1 Is an ERK1/2 Effector That Promotes Invasion and Regulates MMP-1 Expression in Human Melanoma Cells
- (2012) M. B. Weiss et al. CANCER RESEARCH
- Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers
- (2012) C. Parikh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer
- (2011) Yoshimichi Tanaka et al. CANCER BIOLOGY & THERAPY
- Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome
- (2011) Jia Huang et al. GENES CHROMOSOMES & CANCER
- Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile
- (2011) Ardian Latifi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination
- (2011) H. Jo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer
- (2009) Yousif O. Al-Bazz et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
- (2009) Michael A. Bookman et al. JOURNAL OF CLINICAL ONCOLOGY
- Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy
- (2009) N. T. Ihle et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
- (2008) J LOPICCOLO et al. DRUG RESISTANCE UPDATES
- Drug discovery approaches targeting the PI3K/Akt pathway in cancer
- (2008) C Garcia-Echeverria et al. ONCOGENE
- Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis
- (2008) R. Brooks Robey et al. SEMINARS IN CANCER BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started